Sam Klempner, MD, spoke about utilizing ctDNA the treat nonmetastatic gastroesophageal cancers at 2022 IGCC.
A new drug application for futibatinib has been accepted for priority review in patients with previously treated locally advanced or metastatic cholangiocarcinoma with FGFR2 gene rearrangements.
Yelena Y. Janjigian, MD, spoke about which biomarkers were most predictive for treatment of localized gastric cancer.
Yelena Y. Janjigian, MD, spoke about using immunotherapy across settings to treat localized gastric cancer.
In this month’s Letter to the Readers, ONCOLOGY co-editor-in-chief Howard S. Hochster, MD, reviews results of the CIRCULATE-Japan clinical trial that were presented at the 2022 Gastrointestinal Cancers Symposium.
Yelena Y. Janjigian, MD, spoke about using immunotherapy to treat localized gastric cancer.
NUC-1031 plus cisplatin was unlikely to reach a primary end point of improved overall survival in advanced biliary tract cancer, leading to the discontinuation of the phase 3 NuTide:121 trial.
Patients with advanced midgut neuroendocrine tumors experienced a clinically relevant improvement in median overall survival when treated with 177Lu-Dotatate compared with the control of high-dose long-acting octreotide, although the difference was not significant.
The CheckMate 648 trial found that using a combination of nivolumab and chemotherapy or nivolumab plus ipilimumab vs chemotherapy alone improved survival in advanced esophageal squamous-cell carcinoma.
“The pendulum is moving fast towards giving chemotherapy prior to surgery, and the research is going on to continue that trend.”